Src激酶抑制剂PP2对人舌鳞癌Tca8113细胞侵袭和转移的抑制作用

Inhibition of invasion and metastasis of human tonguesquamous cell carcinoma Tca8113 cells by Src kinase inhibitor PP2

目的探讨Src激酶抑制剂PP2对人舌鳞癌Tca8113细胞侵袭、迁移能力的抑制作用。方法采用5、10、20μmol/L Src激酶抑制剂PP2处理Tca8113细胞24 h,分别使用Transwell小室和划痕法,测定PP2对Tca8113细胞侵袭和迁移能力的影响。结果处理24 h后,5、10、20μmol/L Src激酶抑制剂PP2处理组的p-Src表达均较未加药组明显下降(P均<0.05);未加药组及5、10、20μmol/L PP2处理组的穿膜侵袭细胞数分别为(232.76±28.65)个、(186.53±21.34)个、(129.18±17.96)个、(37.82±12.41)个,迁移细胞数分别为(259.38±25.27)个、(193.45±20.18)个、(143.24±18.04)个、(32.94±14.39)个,细胞迁移率分别为(11.51±0.84)%、(8.06±0.51)%、(5.13±0.57)%、(2.18±0.12)%,整体差异均有统计学意义(F=73.852、85.687、48.157,P均=0.000),且与PP2剂量呈负相关。结论 Src激酶抑制剂PP2能够有效抑制人舌鳞癌细胞Tca8113侵袭和迁移能力,并且效果呈浓度依赖性,可能对治疗人舌鳞癌具有一定的临床价值。

Objective To investigate the inhibitory effects of Src kinase inhibitor PP2 on migration and invasion of Tca8113 cells.Methods Tca8113 cells were cultured for 24h with 5mol/L,10mol/L and 20 micron mol/L of Src kinase inhibitor PP2.The effects of PP2 on the invasion and migration of Tca8113 cells were measured with Transwell chamber and scratch method,respectively.Results After the treatment with PP2 for 24h,the expression of p-Src in 5,10,20μmol/L of Src kinase inhibitor PP2 treatment groups was significantly lower than that of the non-drug treatment group(all P<0.05).The number of Tca8113 cells in the non-drug treatment group and the 5,10,and 20μmol/L of Src kinase inhibitor PP2 treatment groups was(232.76±28.65),(186.53±21.34),(129.18±17.96),and(37.82±12.41),respectively;the number of migratory cells was(259.38±25.27),(193.45±20.18),(143.24±18.04),and(32.94±14.39),respectively,the cell migration rate was(11.51±0.84)%,(8.06±0.51)%,(5.13±0.57)%,and(3.18±0.12)%,respectively;the overall difference was statistically significant(F=73.852,85.687,48.157,all P=0.000).It had a negative correlation with PP2 dose.Conclusion Src kinase inhibitor PP2 can effectively inhibit the invasion and migration of Tca8113 cells in the concentration-dependent manner,and it may have certain clinical value in the treatment of human tongue squamous cell carcinoma.